U.S. Markets
US FDA accepts Bristol Myers Squibb's new drug application for Iberdomide in patients with relapsed or refractory multiple Myeloma; target action date of August 17th
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
